Navigation Links
Eli Lilly Partnering Deals and Alliances 2010 to 2017
Date:3/27/2017

LONDON, March 27, 2017 /PRNewswire/ --

Summary
This report provides all the information you require to better understand Eli Lilly and its partnering interests and activities since 2010.

Description
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

The report will be delivered in PDF format within 1 working day of receipt of order. If the CD-Rom version purchased, the report will be sent by courier using express service.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

The initial chapters of this report provide an orientation of deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top companies partnering with the company since 2010. Chapter 3 provides an overview of the leading partnering and M&A deals since 2010 to present date based on headline value.

Chapter 4 provides details on how to approach biopharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where biopharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6 providing a infographic visual summary of the company's partnering activity since 2010 according to deal type, industry sector, phase of development, and therapy area.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners' negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Each contract document is accessible through a link to an online version of the actual contract document as filed with the Securities Exchange Commission.

Analyzing actual company agreements allows assessment of the following:

- What is actually granted by the agreement to the partner company?

- What exclusivity is granted?

- What is the payment structure for the deal?

- How are sales and payments audited?

- What is the deal term?

- How are the key terms of the agreement defined?

- How are IPRs handled and owned?

- Who is responsible for commercialization?

- Who is responsible for development, supply, and manufacture?

- How is confidentiality and publication managed?

- How are disputes to be resolved?

- Under what conditions can the deal be terminated?

- What happens when there is a change of ownership?

- What sublicensing and sub-contracting provisions have been agreed?

- Which boilerplate clauses does the company insist upon?

- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

- Which jurisdiction does the company insist upon for agreement law?

Download the full report: https://www.reportbuyer.com/product/3605571/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eli-lilly-partnering-deals-and-alliances-2010-to-2017-300430064.html


'/>"/>
SOURCE ReportBuyer
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Lilly Statement on Indiana Biosciences Research Institute
2. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
3. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
4. Lilly Declares Third-Quarter 2013 Dividend
5. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
6. The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
7. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
8. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
9. Lilly Reports Second-Quarter 2013 Results
10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
11. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):